{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:58:25Z","timestamp":1781344705602,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Donor lymphocyte infusions (DLI) are an important strategy for managing relapse after allogeneic hematopoietic stem cell transplantation (allo-HCT), yet data on the impact of surveillance frequency and DLI timing remain limited. We retrospectively analyzed 83 adults with acute leukemia or MDS who received DLI after relapse between 2010 and 2022. Monthly molecular monitoring with donor chimerism and genetic markers enabled classification of preemptive DLI at molecular relapse and therapeutic DLI at overt hematologic relapse. Overall survival (OS) was assessed using Kaplan\u2013Meier estimates and Cox regression. Therapeutic DLI was associated with inferior OS compared with preemptive DLI (HR\u2009=\u20090.15 in multivariable analysis, p\u2009&lt;\u20090.001); median OS was 0.47 years in the therapeutic group, while it was not reached after preemptive DLI. GvHD after DLI was associated with better OS (HR\u2009=\u20090.28), consistent with graft-versus-leukemia effects. A longer interval between allo-HCT and relapse also predicted improved survival (HR\u2009=\u20090.78). Delivering DLI at molecular rather than hematologic relapse improved survival, suggesting that close MRD-based surveillance enables earlier detection, timely immunologic intervention, and may improve post-relapse outcomes.<\/jats:p>","DOI":"10.1007\/s00277-026-07090-1","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:14:52Z","timestamp":1780092892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysis"],"prefix":"10.1007","volume":"105","author":[{"given":"Alexander C.","family":"Angleitner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Maulhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Treiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hasenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"B\u00fcntzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald G.","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"11","key":"7090_CR1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/bmt.2016.167","volume":"51","author":"P Tsirigotis","year":"2016","unstructured":"Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J et al (2016) Relapse of AML after hematopoietic stem cell transplantation: Methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transpl 51(11):1431\u20131438. https:\/\/doi.org\/10.1038\/bmt.2016.167 PubMed PMID: 27295272","journal-title":"Bone Marrow Transpl"},{"key":"7090_CR2","doi-asserted-by":"crossref","unstructured":"Biederst\u00e4dt A, Rezvani K, How (2023) I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy [Internet]. Report. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/141\/1\/22\/2073317\/blood_bld-2021-012411-c-main.pdf","DOI":"10.1182\/blood.2021012411"},{"issue":"12","key":"7090_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","volume":"32","author":"CMPW Mandigers","year":"2003","unstructured":"Mandigers CMPW, Verdonck LF, Meijerink JPP, Dekker AW, Schattenberg AVMB, Raemaekers JMM (2003) Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transpl 32(12):1159\u20131163. https:\/\/doi.org\/10.1038\/sj.bmt.1704290 PubMed PMID: 14647270","journal-title":"Bone Marrow Transpl"},{"key":"7090_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328858","author":"K Maurer","year":"2024","unstructured":"Maurer K, Antin JH (2024) The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy. Front Immunol Front Media SA. https:\/\/doi.org\/10.3389\/fimmu.2024.1328858","journal-title":"Front Immunol Front Media SA"},{"key":"7090_CR5","doi-asserted-by":"crossref","unstructured":"Frey NV, Porter DL (2007) Graft-versus-host disease after donor leukocyte infusions: presentation and management. Report","DOI":"10.1016\/j.beha.2008.02.007"},{"key":"7090_CR6","doi-asserted-by":"publisher","unstructured":"Kolb HJ, Schmid C, Barrett AJ, Schendel DJ (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood Am Soc Hematol 767\u2013776. https:\/\/doi.org\/10.1182\/blood-2003-02","DOI":"10.1182\/blood-2003-02"},{"issue":"1","key":"7090_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/bmt.2014.227","volume":"50","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, Shaw B et al (2015) A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transpl 50(1):62\u201367. https:\/\/doi.org\/10.1038\/bmt.2014.227 PubMed PMID: 25310308","journal-title":"Bone Marrow Transpl"},{"key":"7090_CR8","doi-asserted-by":"publisher","unstructured":"Alyea EP, DeAngelo DJ, Moldrem J, Pagel JM, Przepiorka D, Sadelin M et al (2010) NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant 1037\u20131069. https:\/\/doi.org\/10.1016\/j.bbmt.2010.05.005","DOI":"10.1016\/j.bbmt.2010.05.005"},{"issue":"11","key":"7090_CR9","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"A Takami","year":"2014","unstructured":"Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y et al (2014) Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective analysis by the adult acute myeloid leukemia working group of the Japan society for hematopoietic cell transplantation. Biol Blood Marrow Transplant 20(11):1785\u20131790. https:\/\/doi.org\/10.1016\/j.bbmt.2014.07.010","journal-title":"Biol Blood Marrow Transplant"},{"key":"7090_CR10","doi-asserted-by":"crossref","unstructured":"Collins RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplantation [Internet]. Report. Available from: www.nature.com\/bmt","DOI":"10.1038\/sj.bmt.1702555"},{"issue":"10","key":"7090_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/sj.bmt.1705840","volume":"40","author":"PV Campregher","year":"2007","unstructured":"Campregher PV, Gooley T, Scott BL, Moravec C, Sandmaier B, Martin PJ et al (2007) Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transpl 40(10):965\u2013971. https:\/\/doi.org\/10.1038\/sj.bmt.1705840","journal-title":"Bone Marrow Transpl"},{"key":"7090_CR12","doi-asserted-by":"publisher","unstructured":"Cauchois R, Castagna L, Pagliardini T, Harbi S, Calmels B, Bramanti S et al (2019) Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3\u2009+\u2009cells. British Journal of Haematology. Blackwell Publishing Ltd, pp 570\u2013573. https:\/\/doi.org\/10.1111\/bjh.15544","DOI":"10.1111\/bjh.15544"},{"issue":"8","key":"7090_CR13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.bbmt.2017.04.028","volume":"23","author":"CH Yan","year":"2017","unstructured":"Yan CH, Liu Q, fa, Wu Dpei, Zhang X, Xu LP, Zhang X, hui et al (2017) Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease\u2013Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory\/Relapsed Acute Leukemia. Biol Blood Marrow Transplant 23(8):1311\u20131319. https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.028 PubMed PMID: 28483716","journal-title":"Biol Blood Marrow Transplant"},{"key":"7090_CR14","doi-asserted-by":"publisher","unstructured":"Legrand F, Le Floch AC, Granata A, F\u00fcrst S, Faucher C, Lemarie C et al (2017) Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. Bone Marrow Transplantation Nat Publishing Group 620\u2013621. https:\/\/doi.org\/10.1038\/bmt.2016.326","DOI":"10.1038\/bmt.2016.326"},{"key":"7090_CR15","doi-asserted-by":"crossref","unstructured":"Alida Dominietto P, Sarah M, Maurizio A, Flavio P, Giovanna B, Francesca et al (2007) Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood. ;109, Number 11","DOI":"10.1182\/blood-2007-02-072470"},{"key":"7090_CR16","doi-asserted-by":"publisher","unstructured":"Castagna L, Sarina B, Bramanti S, Perseghin P, Mariotti J, Morabito L (2016) Donor lymphocyte infusion after allogeneic stem cell transplantation. Transfusion and Apheresis Science. Elsevier Ltd, pp 345\u2013355. https:\/\/doi.org\/10.1016\/j.transci.2016.05.011","DOI":"10.1016\/j.transci.2016.05.011"},{"issue":"1","key":"7090_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biology of Blood and Marrow Transplantation. 2016 Jan 1;22(1):4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"7090_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 21(3):389\u2013401e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"7090_CR19","volume-title":"Nonparametric Estimation from Incomplete Observations NONPARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATIONS*","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric Estimation from Incomplete Observations NONPARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATIONS*. Journal of the American Statistical Association, Source"},{"issue":"6","key":"7090_CR20","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/trf.12524","volume":"54","author":"Y Tan","year":"2014","unstructured":"Tan Y, Du K, Luo Y, Shi J, Cao L, Zheng Y et al (2014) Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfus (Paris) 54(6):1493\u20131500. https:\/\/doi.org\/10.1111\/trf.12524 PubMed PMID: 24372162","journal-title":"Transfus (Paris)"},{"issue":"4","key":"7090_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbmt.2012.12","volume":"19","author":"P Krishnamurthy","year":"2013","unstructured":"Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM et al (2013) Outcome of Donor Lymphocyte Infusion after T Cell-depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant 19(4):562\u2013568. https:\/\/doi.org\/10.1016\/j.bbmt.2012.12.013 PubMed PMID: 23266740","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"7090_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","volume":"57","author":"C Schmid","year":"2022","unstructured":"Schmid C, Labopin M, Schaap N, Veelken H, Brecht A, Stadler M et al (2022) Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transpl 57(2):215\u2013223. https:\/\/doi.org\/10.1038\/s41409-021-01515-3 PubMed PMID: 34750562","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"7090_CR23","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/leu.2012.135","volume":"26","author":"F Baron","year":"2012","unstructured":"Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C et al (2012) Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 26(12):2462\u20132468. https:\/\/doi.org\/10.1038\/leu.2012.135 PubMed PMID: 22699419","journal-title":"Leukemia"},{"issue":"4","key":"7090_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","volume":"21","author":"T Schroeder","year":"2015","unstructured":"Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK et al (2015) Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant 21(4):653\u2013660. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.016","journal-title":"Biol Blood Marrow Transplant"},{"key":"7090_CR25","doi-asserted-by":"publisher","unstructured":"Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J et al (2018) Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncology. American Medical Association, pp 1245\u20131253. https:\/\/doi.org\/10.1001\/jamaoncol.2018","DOI":"10.1001\/jamaoncol.2018"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07090-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07090-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07090-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:48:15Z","timestamp":1781344095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07090-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["7090"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07090-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the University Medical Center G\u00f6ttingen (approval number: 9\/8\/25).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Due to the retrospective nature of this study, the requirement for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"297"}}